Compare SRFM & CING Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SRFM | CING |
|---|---|---|
| Founded | 2011 | 2012 |
| Country | United States | United States |
| Employees | N/A | 13 |
| Industry | Transportation Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 84.7M | 93.1M |
| IPO Year | 2023 | N/A |
| Metric | SRFM | CING |
|---|---|---|
| Price | $1.13 | $5.24 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | $3.25 | ★ $34.50 |
| AVG Volume (30 Days) | ★ 3.7M | 401.9K |
| Earning Date | 05-12-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 45.69 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $106,557,000.00 | N/A |
| Revenue This Year | $25.90 | N/A |
| Revenue Next Year | $20.72 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.04 | $3.20 |
| 52 Week High | $9.35 | $11.89 |
| Indicator | SRFM | CING |
|---|---|---|
| Relative Strength Index (RSI) | 41.26 | 39.61 |
| Support Level | $1.07 | $4.94 |
| Resistance Level | $1.46 | $6.85 |
| Average True Range (ATR) | 0.13 | 0.44 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 15.38 | 10.53 |
Surf Air Mobility Inc is a regional air mobility platform operating commuter airlines in the United States and expanding an on-demand charter marketplace for passengers in the U.S. and globally. It is also focused on developing a proprietary aviation software, aircraft electrification powertrain technology and services to enable electrification across the regional air mobility sector. The company operates in a single reportable segment, Air Mobility. The Air Mobility segment derives revenue from operating scheduled commercial air service flights, which are sold to the public mainly on a per-seat basis; through subsidized EAS revenue awards from the Department of Transportation; and by operating on-demand flights for customers on an ad-hoc, by request basis.
Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic area to use PTR technology to develop future product candidates.